✦ LIBER ✦

A phase I clinical trial of the mTOR inhibitor everolimus in combination with oral topotecan for patients with recurrent and advanced endometrial cancer

✍ Scribed by M. Abu-Khalaf; A. Santin; E. Ratner; D. Silasi; K. ElSahwi; L. Baker; M. Luther; M. Azodi; T. Rutherford; P. Schwartz

Book ID: 113962955
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 111 KB
Volume: 120
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2010.12.232

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The oral mTOR inhibitor RAD001 (everolim

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics

✍ Ahmad Awada; Fatima Cardoso; Christel Fontaine; Luc Dirix; Jacques De Grève; Chr 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Phase I trial of oral mTOR inhibitor eve

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

✍ Guy Jerusalem; Angelica Fasolo; Veronique Dieras; Fatima Cardoso; Jonas Bergh; L 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 326 KB

Phase I and pharmacokinetic study of cap

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

✍ Maarten J. Deenen, Heinz-Josef Klümpen, Dick J. Richel, Rolf W. Sparidans, Marie 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 299 KB

Phase I clinical trial of survivin-deriv

Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer

✍ Akihiro Miyazaki; Junichi Kobayashi; Toshihiko Torigoe; Yoshihiko Hirohashi; Tak 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB

Phase I clinical trial of lenalidomide i

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

✍ Prasanth Ganesan, Sarina Piha-Paul, Aung Naing, Gerald Falchook, Jennifer Wheler 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 258 KB

A phase 2 study of the oral mammalian ta

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons